BiotechTube
Nirmidas Biotech

Nirmidas Biotech

Palo Alto, United States· Est.
nirmidas.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.3M

Overview

Nirmidas Biotech is a privately-held diagnostics and imaging tools company leveraging its proprietary plasmonic gold (pGOLD) and near-infrared (NIR) technology platforms. Its product portfolio spans from high-accuracy, multiplexed serological assays (including an FDA EUA-authorized COVID-19 test) to advanced in vivo imaging systems for preclinical research. The company is strategically positioned at the intersection of research tools and clinical diagnostics, with affiliations to Janssen Labs, Stanford StartX, and MIT ILP providing validation and network advantages.

Infectious DiseaseOncology (Research Tools)

Technology Platform

Proprietary plasmonic gold (pGOLD) assay platform for high-sensitivity, multiplexed diagnostics and a suite of near-infrared (NIR-I, NIR-II/SWIR) imaging technologies for preclinical in vivo and slide-based imaging.

Funding History

2
Total raised:$15.3M
Series A$12.5M
Seed$2.8M

Opportunities

The growing demand for multiplexed, high-accuracy diagnostic tests for infectious and autoimmune diseases presents a major expansion opportunity for the pGOLD platform.
Furthermore, the transition of deep-tissue NIR-II imaging from a research novelty to a standard tool in preclinical pharmaceutical development offers a significant growth vector for its imaging systems and dye reagents.

Risk Factors

Revenue dependency on COVID-19 diagnostics is a near-term risk as the pandemic market contracts.
In the competitive preclinical imaging space, slower-than-expected adoption of NIR-II technology or failure to displace established competitors could limit growth.
Managing two distinct product lines (diagnostics and hardware) poses operational and financial execution risks.

Competitive Landscape

In diagnostics, Nirmidas competes with large multiplex immunoassay providers (e.g., Luminex, Meso Scale Diagnostics) and rapid test manufacturers. Its pGOLD technology must compete on sensitivity, multiplexing capability, and cost. In imaging, it faces entrenched players like PerkinElmer, Bruker, and LI-COR in the preclinical market, where its competitive edge is its specialized focus on the deep-penetrating NIR-II/SWIR window.

More companies in Diagnostics & Precision Medicine →More companies in United States →